Rate Control for Permanent Atrial Fibrillation A Race (II) Worth Running?⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology. by Passman, Rod
S
c
i
c
r
o
r
p
t
c
i
p
w
a
s
p
s
r
A
w
Journal of the American College of Cardiology Vol. 61, No. 7, 2013
© 2013 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.11.039EDITORIAL COMMENT
Rate Control for
Permanent Atrial Fibrillation
A Race (II) Worth Running?*
Rod Passman, MD
Chicago, Illinois
A brief history of rate control for atrial fibrillation. The
first attempt to control the ventricular rate in a patient with
atrial fibrillation (AF) was likely the description by William
Withering of a patient whose pulse became “more full and
more regular” after the administration of digitalis leaf in
1785 (1). In the 1931 edition of “Diseases of the Heart,” Sir
Thomas Lewis (2) wrote that the goal of rate control for
patients with AF was to “reduce the ventricular rate to about
60 or 70 per min; the second object is to maintain the rate
about 70 to 90 per min in circumstances of rest and light
exercise.” There were obviously no studies at the time to
support this directive. Seventy-five years later national
guidelines recommended similar goals, still with no sup-
porting evidence (3). Regardless, strict rate control of the
ventricular response for patients with AF was accepted,
because it made sense. Faster ventricular rates are often
associated with more symptoms, produce deleterious hemo-
dynamic status through a reduction in diastolic filling times,
and can lead to tachycardia-mediated cardiomyopathy. For
decades, these perceived insights fueled the wholesale adop-
tion of strict rate control strategies, sometimes with delete-
rious effects.
See page 741
The first challenge to these widely held beliefs came from
the results of 2 major rhythm versus rate control trials. Post
hoc analyses of the AFFIRM (Atrial Fibrillation Follow-up
Investigation of Rhythm Management) and RACE (RAte
Control versus Electrical cardioversion) studies showed no
benefit of strict versus lenient rate control, although neither
study was designed to specifically address this issue (4). This
task fell to the RACE II (RAte Control Efficacy in
permanent atrial fibrillation II) study, a randomized trial of
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paper to disclose.a lenient versus strict rate-control strategy that enrolled 314
patients with permanent AF of up to 12-month duration
who were physically active, younger than 80 years of age,
and had a resting heart rate above 80 beats/min (5). Goals
for strict rate control were a resting heart rate of 80
beats/min and 110 beats/min during moderate exercise;
lenient rate control goals were established at 110 beats/
min at rest. Target heart rates were achieved in 98% of the
lenient group but only 67% of the strict rate control group.
As expected, the strict rate control group required a greater
number of therapies at higher dose and more office visits to
achieve target heart rate. During a follow-up period of up to
3 years, no significant differences were found in terms of the
primary composite endpoint of major cardiovascular mor-
bidity or mortality or secondary endpoints that included
symptoms and functional status. On the basis of these
findings, updated guidelines recommend a lenient rate
control strategy for patients with permanent AF although
this time supported by clinical trial data (6).
There were several issues in the original study that
warrant emphasis, the most obvious being that one-third of
those randomized to the strict rate control arm failed to
achieve target heart rates. As a result, the difference in the
mean resting heart rate between the strict and lenient rate
control arms at study end might have been statistically
different but were clinically quite similar to one another.
Although a strategy of strict versus lenient rate control
seemed to offer no benefits, the question still remained as to
whether achieved rate control conferred a better outcome
than lenient rate control. The exploratory analysis of the
original RACE II cohort appearing in this issue of the
Journal by Groenveld et al. (7) takes aim at this question
and in doing so makes an important contribution to the care
of the growing number of patients with permanent AF (8).
trict rate control: attempt versus achievement. The
urrent analysis compares cardiovascular morbidity, mortal-
ty, and quality-of-life endpoints in those with lenient rate
ontrol with those that achieved and failed to achieve strict
ate control at the end of the dose-adjustment phase in the
riginal RACE II study. Nearly all of the patients originally
andomized in the RACE II study were analyzed in the
resent study. Reasons for failed strict rate control included
he absence of AF-related symptoms requiring tighter rate
ontrol, adverse events from the medical therapies, or
nability to achieve target heart rate despite medical thera-
ies. In the end, 608 of the original 614 RACE II cohort
ere included in the sub analysis, with 33% of those
ssigned to strict rate control now analyzed as the failed
trict rate control cohort. At study end, the composite
rimary outcome was reached in 14.2% of those with
uccessful strict rate control, 15.0% of those with failed strict
ate control, and 12.1% of those with lenient rate control.
lthough the confidence intervals for the hazard ratios are
ide, there is no suggestion from the data that those
atients in whom strict rate control was achieved fared any
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strict rate control could not be achieved. These results were
consistent even among those patients with reduced ejection
fraction at baseline, with the caveat that the number of
patients in this group was small. Overall it can be argued
that those with successful strict rate control actually did
worse than their counterparts in the other 2 groups, because
they required higher doses of more medications and needed
more clinic visits to achieve the heart rate goals with no
apparent clinical benefit.
Why is strict rate control no better than lenient rate
control? It seems that the conclusions from the RACE II
study might now be extended to those with attempted or
achieved strict rate control, neither of whom seem to fare
any better compared with those with a lenient rate control
approach in terms of cardiovascular morbidity, mortality, or
symptoms. Although a little rate control might in fact be
good enough, some limitations remain. The original RACE
II study found that, at the end of the follow-up period, the
mean resting heart rate in the lenient-control group was
85  14 beats/min compared with 76  14 beats/min in
he strict rate control group. In the present analysis, mean
eart rates in those with achieved strict rate control or
ailed strict rate control, or randomized to lenient rate
ontrol were 75  14 beats/min, 78  12 beats/min, and
5  13 beats/min, respectively. Even though the goal for
enient rate control was 110 beats/min, only 23% in the
riginal cohort had heart rates 100 beats/min. In the end,
t might be difficult to expect that differences in ventricular
esponse of 10 beats/min could significantly impact the
omposite endpoint or improve symptoms in the permanent
F population, especially because most patients in the
enient rate control group were not even tachycardiac most
f the time. More importantly, the number and doses of
edical therapies needed to achieve strict rate control might
ffset any benefits of a modestly lower heart rate. Those
atients in whom strict rate control was achieved were more
ikely to receive double or even triple atrioventricular nodal
locking agents, often at significantly higher doses.
hether these drugs alone or in combination contributed to
ncreased event rates is purely speculative, although it is
nteresting to note that those who were assigned to but did
ot achieve strict rate control had numerically greater
umbers of deaths from cardiovascular causes, cardiac ar-
hythmic death, cardiac non-arrhythmic death, congestive
eart failure, need for pacemaker implantation, and death
rom any cause. One possibility is that these individuals
xperienced only the adverse effects of the prescribed agents
ut derived none of the benefits. Alternatively, one could
ypothesize that some of those individuals that can be
dequately rate controlled with fewer number and lower
oses of medical therapies are inherently better off, perhaps
s a result of intrinsic increases in parasympathetic tone.
Similar arguments might apply to the quality-of-life
ndpoints of the analysis. At baseline, more than one-half of
he patients had symptoms including palpitations, dyspnea,nd fatigue with no significant difference between the 3
roups. By study end, all groups showed some overall
mprovement, particularly when it came to palpitations.
ontrary to expectations, however, patients with successful
trict rate control seemed to derive the least reduction in
verall symptoms. Although it is possible that some com-
laints such as dyspnea and fatigue are unrelated to ventric-
lar rate, one must also consider the possibility that once
gain the medical therapies required to achieve adequate
ate control also create adverse symptoms that offset the
alutary effects of slowed ventricular conduction. This con-
ept is supported by the results of multiple “ablate and pace”
tudies, where strict rate control is achieved through atrio-
entricular nodal ablation without the use of medical ther-
pies. Although these patients are invariably more symp-
omatic and have faster ventricular rates at baseline, this
pproach is almost universally associated with improve-
ents in cardiac symptoms scores and quality-of-life
easures (9).
linical implications of the RACE II study. In the wake
f the AFFIRM, RACE, and RACE II studies, some
ight be tempted to take a nihilistic approach to AF
herapies, because the evidence supporting a major morbid-
ty or mortality benefit from rhythm control and now strict
ate control strategies with medical therapies has been
nderwhelming. One unifying theme between the failure of
ate and rhythm control strategies to show an improvement
n these areas might lie in the limited efficacy of the available
rug therapies and the adverse effects of the medications
sed to achieve the stated goals. Still, important lessons can
e learned. First and foremost, there is little reason to do
nything in medicine unless we can improve the duration or
he quality of life. Strict rate control for permanent AF
eems to do neither and therefore is not a race worth
unning. In contrast, a resting ventricular rate of 110
eats/min seems reasonable for most permanent AF pa-
ients in the absence of significant symptoms. Whether the
ame recommendation applies to patients with reduced
jection fraction is still uncertain, given the small proportion
f enrollees with ejection fraction 40% and median
ollow-up times too short to allow tachycardia-mediated
ardiomyopathy to manifest in some susceptible individuals
10). On a grander scale, the current analysis provides yet
nother example of how seemingly logical treatment strat-
gies fail under the scrutiny of a rigorous clinical trial.
ecause it is estimated that only 1 in 9 American College of
ardiology/American Heart Association guideline recom-
endations are supported by the highest levels of evidence,
his will certainly not be the last (11).
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